ABL Bio Inc. (KOSDAQ: A298380)
Health Care · Biotechnology · KR
₩75,200.00
-10.58% today · -15.3% 1Y
ABL Bio Inc. (KOSDAQ: A298380) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.04B.
Over the last twelve months the share price has lost 15.3%, trading between 59.80K and 257.50K.
Tweenvest scores ABL Bio Inc. across four factors: quality 45/100, value 48/100. Its strongest factor is value.
A298380 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.04B
- Revenue (TTM)
- $22.14M
- P/E
- —
- EPS
- -1,424.72
- Dividend yield
- —
- Beta (5Y)
- 0.27
- 52-week high
- ₩257,500.00
- 52-week low
- ₩59,800.00
- Avg volume (3M)
- —
- Shares outstanding
- 55.99M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.29 | +0.67% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.18 | +0.08% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.42 | +1.14% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $554.25 | +1.22% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $836.21 | +0.93% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $156.25 | +12.50% |
Figures last refreshed Aug 18, 2026.